National, Non Interventional Study of Invasive Pneumococcal Disease in Children and Newbor
After 7 then 13 valent pneumococcal conjugate vaccine (PCV) implementation in France in children, we will evaluate the impact of this vaccination on invasive pneumococcal disease (IPD). We will describe the clinical characteristics of IPD, pneumococcus serotyping, underlying conditions and vaccination status.
| Condition(s) | Pneumococcal Infections, Pneumococcal Conjugate Vaccine, Antibiotic Treatment, Mortality |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | After 7 then 13 valent pneumococcal conjugate vaccine (PCV) implementation in France in children, we will evaluate the impact of this vaccination on invasive pneumococcal disease (IPD). We will describe the clinical characteristics of IPD, pneumococcus serotyping, underlying conditions and vaccination status. |
| Who can participate | Inclusion Criteria: * Isolate of Streptococcus pneumoniae from at least one blood culture, or pleural fluid, or joint fluid, or cerebrospinal fluid or other normally sterile body site, or if there is a positive blood polymerase chain reaction (PCR). Exclusion Criteria: * Pneumococcal strain not transmetted to National Reference Center for Pneumococci or to Regional Pneumococci Observatory |
| Ages | 1 Day to 18 Years |
| Sex | All |
| Lead sponsor | Association Clinique Thérapeutique Infantile du val de Marne |
| Locations | Créteil, France |
| Start date | 2010-12-13 |
| NCT ID | NCT04664556 |
| Official listing | https://clinicaltrials.gov/study/NCT04664556 |